Can the US Afford to Ignore Cost-effectiveness Evidence?

James Chambers

Seminar Briefing from Office of Health Economics

Abstract: Cost-effectiveness analysis plays a limited role in US health care compared to many other countries. In this Seminar Briefing, Dr James Chambers, Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, considers the current use of cost-effectiveness analysis in the US and explores the potential value of including it in decisions about coverage for medical technology by Medicare (the national public health insurance programme primarily for people 65+ years of age). He reviews the current barriers in the US – both legislative and otherwise – to wider adoption of cost-effectiveness as a basis for health care decisions and notes attempts to use payment reform instead to increase incentives for greater efficiency.

Keywords: Can; the; US; Afford; to; Ignore; Cost-effectiveness; Evidence? (search for similar items in EconPapers)
JEL-codes: I1 (search for similar items in EconPapers)
Date: 2014-03-01
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.ohe.org/publications/can-us-afford-ign ... re-ce-chambers-2014/ (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ohe:sembri:000074

Access Statistics for this paper

More papers in Seminar Briefing from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).